242 related articles for article (PubMed ID: 22644306)
1. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling.
Dubrovska A; Hartung A; Bouchez LC; Walker JR; Reddy VA; Cho CY; Schultz PG
Br J Cancer; 2012 Jun; 107(1):43-52. PubMed ID: 22644306
[TBL] [Abstract][Full Text] [Related]
2. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells.
Selever J; Gu G; Lewis MT; Beyer A; Herynk MH; Covington KR; Tsimelzon A; Dontu G; Provost P; Di Pietro A; Boumendjel A; Albain K; Miele L; Weiss H; Barone I; Ando S; Fuqua SA
Clin Cancer Res; 2011 Oct; 17(20):6510-21. PubMed ID: 21878538
[TBL] [Abstract][Full Text] [Related]
3. Tamoxifen-resistant breast cancer cells possess cancer stem-like cell properties.
Liu H; Zhang HW; Sun XF; Guo XH; He YN; Cui SD; Fan QX
Chin Med J (Engl); 2013 Aug; 126(16):3030-4. PubMed ID: 23981606
[TBL] [Abstract][Full Text] [Related]
4. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Wu X; Zahari MS; Renuse S; Nirujogi RS; Kim MS; Manda SS; Stearns V; Gabrielson E; Sukumar S; Pandey A
Mol Cell Proteomics; 2015 Nov; 14(11):2887-900. PubMed ID: 26330541
[TBL] [Abstract][Full Text] [Related]
6. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen resistance induction results in the upregulation of ABCG2 expression and mitoxantrone resistance in MCF-7 breast cancer cells.
Ghalehno AD; Abdi H; Boustan A; Jamialahmadi K; Mosaffa F
Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3723-3732. PubMed ID: 37310508
[TBL] [Abstract][Full Text] [Related]
8. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
Wang L; Zhang X; Wang ZY
Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
[TBL] [Abstract][Full Text] [Related]
9. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
10. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
11. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells.
Yang S; Lee JY; Hur H; Oh JH; Kim MH
BMB Rep; 2018 Sep; 51(9):450-455. PubMed ID: 29804556
[TBL] [Abstract][Full Text] [Related]
13. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
[TBL] [Abstract][Full Text] [Related]
14. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
15. Sox2 promotes tamoxifen resistance in breast cancer cells.
Piva M; Domenici G; Iriondo O; Rábano M; Simões BM; Comaills V; Barredo I; López-Ruiz JA; Zabalza I; Kypta R; Vivanco Md
EMBO Mol Med; 2014 Jan; 6(1):66-79. PubMed ID: 24178749
[TBL] [Abstract][Full Text] [Related]
16. A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.
Ojo D; Wu Y; Bane A; Tang D
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):735-745. PubMed ID: 29248549
[TBL] [Abstract][Full Text] [Related]
17. The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
Xu D; Zhang Y; Jin F
BMC Cancer; 2021 Dec; 21(1):1321. PubMed ID: 34886806
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan.
Hiscox S; Baruha B; Smith C; Bellerby R; Goddard L; Jordan N; Poghosyan Z; Nicholson RI; Barrett-Lee P; Gee J
BMC Cancer; 2012 Oct; 12():458. PubMed ID: 23039365
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
